United Kingdom (UK)
Recombinant monoclonal antibody to Vaccinia A33 glycoprotein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma A2C7.
Immunogen: This antibody was prepared by intranasally infecting BALB/c mice with an attenuated vaccinia virus (VACV) mutant, followed by a boost with an intravenous injection of UV-inactivated WT VACV.
Specificity: This antibody is specific for the VACV antigen A33, a viral glycoprotein associated with the outer membrane of extracellular enveloped viruses. A33 is known to elicit protective antibody responses.
Application Notes: The specificity of this antibody for VACV has been confirmed by IF assays (Meng, 2011). This antibody exhibited strong complement-mediated neutralization of the extracellular enveloped form of vaccinia virus in the presence of complement, and was able to protect mice against weight loss and death following an in vivo VACV challenge (Matho, 2015).
Antibody first published in:
Meng et al. Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus Virology, 2011, Vol.409(2), pp.271-279 PMID:21056889
Note on publication:
Describes the original generation of this antibody, along with a panel of other anti-VACV monoclonal antibodies, by characterizing B cell hybridomas from a mouse immunized with VACV.